目的讨论基因重组链激酶在治疗高血压脑出血破入脑室中的作用。方法通过前瞻性对照研究观察近远期疗效。结果基因重组链激酶组较尿激酶组术后第 1天平均引流量及第 4天脑室血肿减少量差异具有显著性 ;术后病死率及功能预后的差异亦有显著性。结论基因重组链激酶比尿激酶能更好地溶解引流脑室内血肿 ,明显地降低病死率及病残率 Objective To discuss the role of gene recombinant streptokinase in the treatment of hypertensive intracerebral hemorrhage. Methods The prospective and controlled study was used to observe the short-term and long-term effects. Results There was significant difference between the mean drainage volume of gene recombinant streptokinase group and urokinase group on the first day and the decrease of ventricular hematoma on the fourth day after operation. The difference of postoperative mortality and function prognosis was also significant. Conclusions Gene recombinant streptokinase can dissolve the drainage of intraventricular hematoma better than urokinase and significantly reduce the mortality and morbidity